To the Editor: Stone et al. (Aug. 3 issue)1 found that adding midostaurin to a standard chemotherapy regimen containing daunorubicin at a dose of 60 mg per square meter of body-surface area significantly prolonged overall and event-free survival among patients with acute myeloid leukemia (AML) and a FLT3 mutation (point mutation in the tyrosine kinase domain [TKD] or internal tandem duplication [ITD] mutation) as compared with placebo plus standard chemotherapy. In a previous study, a nonsignificant trend for benefit beyond 12 months was shown in patients with a FLT3 mutation of the ITD subtype who received daunorubicin at a dose . . .

中文翻译：

---

米哚妥林在FLT3 -Mutated急性髓系白血病

致编辑：Stone等。（8月3日）1发现，在含有柔红霉素的标准化疗方案中以每平方米体表面积60 mg的剂量添加米多骨苷能显着延长急性髓细胞性白血病（AML）患者的总体生存率和无事件生存期，与安慰剂加标准化疗相比，FLT3突变（酪氨酸激酶结构域[TKD]中的点突变或内部串联重复[ITD]突变）。在先前的研究中，在接受剂量柔红霉素的ITD亚型FLT3突变患者中，超过12个月的获益无明显趋势。。。